KYTX Kyverna Therapeutics, Inc.
USHealthcareAs of 2026-07-09 12:18
Why KYTX matters now
Kyverna Therapeutics, Inc. (KYTX) is a US stock in Healthcare. The latest InvestLog snapshot shows $9.78 with -1.33% on the session and $428.2M in market capitalization; recent performance reads 1-month -7.24% and YTD -14.15%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-39.7M, and EPS of $-0.66. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -42.7%.
The latest indexable market news headline is "Kyverna Therapeutics: The Autoimmune CAR T Beachhead Is Bigger Than SPS" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $25.00; recent insider activity includes Aktar Mert filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.49
P/S
0.00
EV/EBITDA
-2.31
DCF Value
$2.04
FCF Yield
-42.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-81.9%
ROA
-60.9%
ROIC
-71.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-39.7M | $-0.66 |
| Q4 2025 | $0.00 | $-37.8M | $-0.80 |
| FY 2025 | $0.00 | $-161.3M | $-3.64 |
| Q3 2025 | $0.00 | $-36.8M | $-0.85 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$25.00
Target (Median)
$25.00
Target Range
$25.00 - $25.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.96
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise specializing in the advancement of cell-based therapies to treat individuals suffering from autoimmune disorders. Its primary experimental therapy, KYV-101, an autologous CD19 CAR T-cell candidate, is currently undergoing Phase I clinical evaluation for lupus nephritis and systemic sclerosis, and has progressed to Phase II studies for myasthenia gravis and multiple sclerosis. Furthermore, the company's pipeline includes KYV-201, an allogeneic CD19 CAR T-cell candidate still in preclinical development, designed to address a variety of autoimmune conditions. Kyverna is also exploring therapeutic solutions for other autoimmune diseases, such as inflammatory bowel disease, encompassing Crohn's disease and ulcerative colitis. The firm has established strategic alliances, including a licensing and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product, and a partnership with Kite for programs aimed at treating, diagnosing, and preventing autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. Incorporated in 2018 and headquartered in Emeryville, California, Kyverna Therapeutics, Inc. was formerly known as BAIT Therapeutics, Inc. until its name change in October 2019.